EU/3/14/1260

Table of contents

About

On 26 March 2014, orphan designation (EU/3/14/1260) was granted by the European Commission to Pharnext SAS, France, for fixed-dose combination of (R-S) baclofen, naltrexone hydrochloride and D-sorbitol for the treatment of Charcot-Marie-Tooth disease type 1A.

In May 2016, Pharnext SAS changed name to Pharnext SA.

Key facts

Active substance
Fixed-dose combination of (R-S) baclofen, naltrexone hydrochloride and D-sorbitol
Disease / condition
Treatment of Charcot-Marie-Tooth disease type 1A
Date of first decision
26/03/2014
Outcome
Positive
EU designation number
EU/3/14/1260

Sponsor's contact details

Pharnext SA
11, rue des Peupliers
92130 Issy-les-Moulineaux
France
Tel. +33 141 0922 55
E-mail: contact@pharnext.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating